Shanghai Shen Lian Biomedical Corporation (SHA:688098)
8.04
-0.14 (-1.71%)
Oct 14, 2026, 1:34 PM CST
SHA:688098 Revenue
Shanghai Shen Lian Biomedical had revenue of 49.32M CNY in the quarter ending June 30, 2026, with 14.75% growth. This brings the company's revenue in the last twelve months to 278.46M, down -6.80% year-over-year. In the year 2025, Shanghai Shen Lian Biomedical had annual revenue of 288.27M, down -4.99%. That makes Shanghai Shen Lian Biomedical the 29,230th largest company in the world by revenue and 4,913th in China.
Revenue (ttm)
278.46M
Revenue Growth
-6.80%
P/S Ratio
12.06
Revenue / Employee
740.59K
Employees
376
Market Cap
3.36B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 288.27M | -15.15M | -4.99% |
| Dec 31, 2024 | 303.41M | 1.93M | 0.64% |
| Dec 31, 2023 | 301.49M | -27.11M | -8.25% |
| Dec 31, 2022 | 328.59M | -29.83M | -8.32% |
| Dec 31, 2021 | 358.43M | 20.70M | 6.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Baolingbao Biology | 2.85B |
| Xiangxue Pharmaceutical | 1.48B |
| Qingdao Vland Biotech INC. | 1.42B |
| Pulike Biological Engineering | 1.02B |
| Landfar Bio-medicine | 660.26M |
| Lifecome Biochemistry | 470.43M |
| Guanhao Biotech | 361.40M |
| Jiangsu Bioperfectus Technologies | 310.89M |